drugset / Trial / NCT05750355
Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a single-dose orally administered, dose-escalation, single-center, randomized, double-blind, placebo-parallel controlled clinical study evaluating the effect of TPN171H tablets on QT/QTc interval in healthy subjects.The main objective was to evaluate the effect of TPN171H tablets on QT/QTc interval in healthy Chinese subjects after a single oral administration.
Timeline
- Start
- 2022-10-10
- Primary completion
- 2022-12-07
- Completion
- 2022-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPN171H | Unknown | 10 mg | Oral |
| Subject | TPN171H | Unknown | 30 mg | Oral |
| Subject | TPN171H | Unknown | 40 mg | Oral |
| Subject | TPN171H | Unknown | 50 mg | Oral |
Indications
No indication recorded.